Tower Research Capital LLC TRC Boosts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Tower Research Capital LLC TRC raised its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 142.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 8,472 shares of the biopharmaceutical company's stock after buying an additional 4,978 shares during the quarter. Tower Research Capital LLC TRC's holdings in Regeneron Pharmaceuticals were worth $6,035,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Willner & Heller LLC grew its holdings in Regeneron Pharmaceuticals by 3.9% in the fourth quarter. Willner & Heller LLC now owns 399 shares of the biopharmaceutical company's stock worth $284,000 after purchasing an additional 15 shares during the period. OLD Second National Bank of Aurora increased its position in Regeneron Pharmaceuticals by 0.5% during the 4th quarter. OLD Second National Bank of Aurora now owns 2,843 shares of the biopharmaceutical company's stock valued at $2,025,000 after buying an additional 15 shares in the last quarter. Rakuten Securities Inc. raised its stake in Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 15 shares during the last quarter. TD Private Client Wealth LLC grew its stake in shares of Regeneron Pharmaceuticals by 9.6% in the fourth quarter. TD Private Client Wealth LLC now owns 171 shares of the biopharmaceutical company's stock worth $122,000 after acquiring an additional 15 shares during the last quarter. Finally, Manchester Capital Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 12.6% during the fourth quarter. Manchester Capital Management LLC now owns 161 shares of the biopharmaceutical company's stock valued at $115,000 after acquiring an additional 18 shares in the last quarter. Institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock traded up $2.88 during trading hours on Friday, hitting $602.64. The company's stock had a trading volume of 964,377 shares, compared to its average volume of 723,778. The company has a market cap of $65.88 billion, a PE ratio of 15.74, a PEG ratio of 2.34 and a beta of 0.44. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The business has a 50 day moving average price of $637.38 and a two-hundred day moving average price of $725.82. Regeneron Pharmaceuticals, Inc. has a 12-month low of $525.99 and a 12-month high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The company had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. During the same period in the previous year, the firm earned $11.86 EPS. The firm's revenue was up 10.3% compared to the same quarter last year. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were given a dividend of $0.88 per share. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.58%. Regeneron Pharmaceuticals's dividend payout ratio is 2.30%.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the stock. TD Cowen reduced their price objective on shares of Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a "buy" rating for the company in a research note on Tuesday, February 4th. Truist Financial decreased their price objective on shares of Regeneron Pharmaceuticals from $1,004.00 to $975.00 and set a "buy" rating for the company in a report on Wednesday. UBS Group lowered Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $1,130.00 to $738.00 in a report on Thursday, January 16th. Robert W. Baird dropped their price objective on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research report on Friday. Finally, Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Wednesday, February 5th. One research analyst has rated the stock with a sell rating, four have given a hold rating, nineteen have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $945.32.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.